OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $900.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-06
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $900.00K, a 12.50% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $2.90M, a 27.50% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $100.00K, a 50.00% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $800.00K, a 0.00% change year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $8.90M, a 45.90% increase from fiscal 2022.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $6.10M, a 134.62% increase from fiscal 2021.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $2.60M, a 420.00% increase from fiscal 2020.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $500.00K, a 50.00% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $900.00K 10-Q · filed 2026-08-06 | $3.80M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $2.90M 10-Q · filed 2026-05-08 | |||
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-05 | $900.00K derived: sum of 2 quarters · filed 2026-08-06 | $4.90M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $800.00K 10-Q · filed 2026-08-06 | $4.70M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $4.00M 10-Q · filed 2026-05-08 | |||
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-05 | $1.00M derived: sum of 2 quarters · filed 2025-11-05 | $6.00M 10-Q · filed 2025-11-05 | $6.40M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $800.00K 10-Q · filed 2025-08-04 | $5.70M 10-Q · filed 2025-08-04 | $6.20M derived: sum of 3 quarters · filed 2025-08-04 | $6.60M derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | $5.00M 10-Q · filed 2025-05-09 | $5.40M derived: sum of 2 quarters · filed 2025-05-09 | $5.80M derived: sum of 3 quarters · filed 2025-05-09 | $8.30M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $800.00K derived: sum of 2 quarters · filed 2024-11-14 | $3.30M derived: sum of 3 quarters · filed 2024-11-14 | $8.90M 10-K · filed 2024-04-16 |
| 2023-09-30 | $400.00K 10-Q · filed 2024-11-14 | $2.90M derived: sum of 2 quarters · filed 2024-11-14 | $8.50M 10-Q · filed 2024-11-14 | $10.00M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.50M 10-Q · filed 2024-08-08 | $8.10M 10-Q · filed 2024-08-08 | $9.60M derived: sum of 3 quarters · filed 2024-08-08 | $10.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.60M 10-Q · filed 2024-05-14 | $7.10M derived: sum of 2 quarters · filed 2024-05-14 | $7.70M derived: sum of 3 quarters · filed 2024-05-14 | $8.80M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $2.10M derived: sum of 2 quarters · filed 2024-04-16 | $3.20M derived: sum of 3 quarters · filed 2024-04-16 | $6.10M 10-K · filed 2024-04-16 |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-09 | $1.70M derived: sum of 2 quarters · filed 2023-11-09 | $4.60M 10-Q · filed 2023-11-09 | $6.40M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.10M 10-Q · filed 2023-08-21 | $4.00M 10-Q · filed 2023-08-21 | $5.80M derived: sum of 3 quarters · filed 2023-08-21 | $5.90M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $2.80M 10-Q · filed 2023-05-05 | $4.70M derived: sum of 2 quarters · filed 2023-05-05 | $4.80M derived: sum of 3 quarters · filed 2023-05-05 | $5.10M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.00M derived: sum of 2 quarters · filed 2023-02-28 | $2.30M derived: sum of 3 quarters · filed 2023-02-28 | $2.60M 10-K · filed 2023-02-28 |
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-08 | $400.00K derived: sum of 2 quarters · filed 2022-11-08 | $700.00K 10-Q · filed 2022-11-08 | $900.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-05 | $600.00K 10-Q · filed 2022-08-05 | $800.00K derived: sum of 3 quarters · filed 2022-08-05 | $900.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $300.00K 10-Q · filed 2022-05-06 | $500.00K derived: sum of 2 quarters · filed 2022-05-06 | $600.00K derived: sum of 3 quarters · filed 2022-05-06 | $700.00K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $300.00K derived: sum of 2 quarters · filed 2022-02-28 | $400.00K derived: sum of 3 quarters · filed 2022-02-28 | $500.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $100.00K 10-Q · filed 2021-11-09 | $200.00K derived: sum of 2 quarters · filed 2021-11-09 | $300.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $100.00K 10-Q · filed 2021-08-06 | $200.00K 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $100.00K 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $1.00M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |